"Uridine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.
| Descriptor ID |
D014542
|
| MeSH Number(s) |
D03.383.742.686.850.877 D13.695.740.850.877 D13.695.827.919.877
|
| Concept/Terms |
Uridine Monophosphate- Uridine Monophosphate
- Monophosphate, Uridine
- Uridine 5'-Monophosphate
- 5'-Monophosphate, Uridine
- Uridine 5' Monophosphate
- Uridylic Acid
- Acid, Uridylic
- Uridylic Acids
- Acids, Uridylic
- UMP
|
Below are MeSH descriptors whose meaning is more general than "Uridine Monophosphate".
Below are MeSH descriptors whose meaning is more specific than "Uridine Monophosphate".
This graph shows the total number of publications written about "Uridine Monophosphate" by people in this website by year, and whether "Uridine Monophosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uridine Monophosphate" by people in Profiles.
-
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl. 2016 11; 22(11):1536-1543.
-
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
-
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
-
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015 May 05; 162(9):619-29.
-
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May; 61(5):1485-94.
-
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
-
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health. 2015; 10(3):296-317.
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
-
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology. 2014 Jul; 60(1):12-4.